Summary of the Interim Report for Q4 2023
2023 | 2022 | 2023 | 2022 | |
TSEK | Oct-Dec | Oct-Dec | Jan-Dec | Jan-Dec |
Other income | 1.315 | 1.964 | 9.378 | 5.183 |
Profit/loss before depreciation (EBITDA) | -6.662 | -12.491 | -27.266 | -39.987 |
Operating profit/loss befor net financials | -6.662 | -12.491 | -27.037 | -39.987 |
Net financials | 193 | 87 | 229 | 109 |
Netprofit/loss for the period | -6.469 | -12.432 | -27.037 | -39.906 |
Earnings per share (SEK) | -0,13 | -0,40 | -0,53 | -1,28 |
Highlights during Q4 2023
December 12 ,Biosergen's Partner Alkem Laboratories Submits Clinical Trial Application for First Patient Study with BSG005 in Invasive Fungal Infections inIndia as a Rescue Therapy
Highlights after the period
February 12 ,Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection.January 30 ,Biosergen carries out a rights issue of units of approximatelySEK 40.5 million , and secures bridge loanJanuary 12 , Biosergen Announces Leadership Transition:Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor
The Financial report can be found on our website: https://biosergen.net/investors/filings
For further information about
Telephone: +45 3135 5707
E-mail: tine.olesen@biosergen.net
Telephone: +45 4014 5059
Email: niels.laursen@biosergen.net
The Company's Certified Adviser is
ABOUT
https://news.cision.com/biosergen-ab/r/biosergen-publishes-interim-report-for-fourth-quarter-2023,c3938055
https://mb.cision.com/Main/20568/3938055/2637720.pdf
https://mb.cision.com/Public/20568/3938055/b44a1ead4e08cf5f.pdf
(c) 2024 Cision. All rights reserved., source